American firms have a long history of running into competition concerns when trying to buy UK-based chipmaker Plessey.
Month: March 2020
Textio extracts $12m
Bloomberg Data returned for a round that lifted the overall funding for augmented text software developer Textio to more than $41m.
Yuanfudao marks off $1bn series G
The online education provider pushed its total funding past $1.5bn in a round co-led by Tencent that valued it at $7.8bn.
Hualan Biological Vaccines hooks $292m
Hillhouse Capital and Chen Yi Investment are making a secondary investment in the Hualan Biological Engineering spinoff which is now valued at more than $1.9bn.
Sunyur Network sources series A funding
SiE Consulting was among the existing backers that joined Sequoia China for a $14.1m round that doubled the IT procurement startup’s total funding.
Exor mobilises $200m for Via Transportation
Transportation services provider Via raised the money as part of a series E round also featuring Shell, Hearst Ventures and Mori Building valuing it at $2.25bn.
Middaugh to maintain $1bn Microsoft carbon fund
Brandon Middaugh has been promoted from Microsoft’s cloud energy and sustainability team to direct the Climate Innovation Fund it disclosed in January.
Hooq clasps liquidation option
The online streaming service, which had raised $95m from SingTel, Warner Bros and Sony Pictures, has filed for liquidation following a failure to scale in the fact of stiff competition.
Huilianyi hauls in series C-plus funding
SoftBank China Venture Capital returned for a $42.3m round that will support the international growth of Huilianyi’s expenses management software.
Stripe works Fast in $20m series A
Fast will put the funding into recruitment and the international roll-out of its rapid e-commerce login and checkout system.
Avail puts $15m in its eyeline
Avail Medsystems, a remote medical device startup which counts Baidu Ventures as an investor, has captured $15m in new funding.
WhitePlus washes up with fresh funding
YJ Capital returned to reinvest in a $13.9m round for the laundry app developer alongside Globis Capital Partners and Raksul.
GSK hardens its cancer strategy through Lyell
It is the sort of line to awaken the curiosity in an annual report: “Cash payments to acquire equity investments amounted to £258m [$314m] (2018 – £309m), primarily relating to Lyell Immunopharma.”
GSK displays Lyell Immunopharma investment
The corporate owned a 15% stake in immunotherapy developer Lyell, which recently raised $493m, with a fair value of $203m as of the end of 2019.